
Traumatic Brain Injury (TBI) - Drug Pipeline Landscape, 2023
Description
Traumatic Brain Injury (TBI) - Drug Pipeline Landscape, 2023
Traumatic Brain Injury (TBI) is a disruption in the normal function of the brain that can be caused by a blow, bump or jolt to the head, the head suddenly and violently hitting an object or when an object pierces the skull and enters brain tissue. Traumatic brain injury is the leading cause of death and disability worldwide and, can be fatal especially in children and adolescents.
The most common cause of traumatic brain injury (TBI) is traffic accidents, which are mostly obstructive and are accompanied by physical or neurological disorders caused by multiple or local injuries and caused by external impact caused by coup injury that occurs on the part hitting an object and contrecoup injury that occurs on the other side due to acceleration.
Signs and symptoms of traumatic brain injury (TBI) includes loss of or decreased consciousness Loss of memory for events before or after the event (amnesia), focal neurological deficits such as muscle weakness, loss of vision, change in speech, alteration in mental state such as disorientation, slow thinking or difficulty concentrating
Doctors most often diagnose traumatic brain injury (TBI) by quick examination of the entire body is performed, followed by a complete neurological examination. The neurological examination includes an assessment utilizing the Glasgow Coma Scale (GCS), the presence of a wide or dilated pupil on only one side suggests a large mass lesion may be present. brainstem reflexes including gag and corneal (blink) may also be tested, a computed tomography scan (CT or CAT scan) is the gold standard for the radiological assessment of a TBI.
Surgery is the most common treatment for traumatic brain injury which is performed to remove a large hematoma or contusion that is significantly compressing the brain or raising the pressure within the skull.
Report Highlights
Global Insight Service’s, Traumatic Brain Injury (TBI) - Drug Pipeline Landscape, 2023 report provides an overview of the Traumatic Brain Injury (TBI) pipeline drugs. This report covers detailed insights on Traumatic Brain Injury (TBI) drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Traumatic Brain Injury (TBI) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Traumatic Brain Injury (TBI) is a disruption in the normal function of the brain that can be caused by a blow, bump or jolt to the head, the head suddenly and violently hitting an object or when an object pierces the skull and enters brain tissue. Traumatic brain injury is the leading cause of death and disability worldwide and, can be fatal especially in children and adolescents.
The most common cause of traumatic brain injury (TBI) is traffic accidents, which are mostly obstructive and are accompanied by physical or neurological disorders caused by multiple or local injuries and caused by external impact caused by coup injury that occurs on the part hitting an object and contrecoup injury that occurs on the other side due to acceleration.
Signs and symptoms of traumatic brain injury (TBI) includes loss of or decreased consciousness Loss of memory for events before or after the event (amnesia), focal neurological deficits such as muscle weakness, loss of vision, change in speech, alteration in mental state such as disorientation, slow thinking or difficulty concentrating
Doctors most often diagnose traumatic brain injury (TBI) by quick examination of the entire body is performed, followed by a complete neurological examination. The neurological examination includes an assessment utilizing the Glasgow Coma Scale (GCS), the presence of a wide or dilated pupil on only one side suggests a large mass lesion may be present. brainstem reflexes including gag and corneal (blink) may also be tested, a computed tomography scan (CT or CAT scan) is the gold standard for the radiological assessment of a TBI.
Surgery is the most common treatment for traumatic brain injury which is performed to remove a large hematoma or contusion that is significantly compressing the brain or raising the pressure within the skull.
Report Highlights
Global Insight Service’s, Traumatic Brain Injury (TBI) - Drug Pipeline Landscape, 2023 report provides an overview of the Traumatic Brain Injury (TBI) pipeline drugs. This report covers detailed insights on Traumatic Brain Injury (TBI) drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Traumatic Brain Injury (TBI) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
203 Pages
- 1. Introduction
- 1.1 Traumatic Brain Injury (TBI) – Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview – Traumatic Brain Injury (TBI)
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Traumatic Brain Injury (TBI) – Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs - Phase III
- 5.1.1 Cytoflavin
- 5.1.2 VAS203
- 5.2 Clinical Stage Drugs - Phase II
- 5.2.1 AVP-786
- 5.2.2 CEVA101
- 5.2.3 Cinryze
- 5.2.4 HB-adMSCs
- 5.2.5 MR-301
- 5.2.6 Nerinetide
- 5.2.7 OXE103
- 5.2.8 SB623
- 5.2.9 VOLT02
- 5.3 Clinical Stage Drugs - Phase I
- 5.3.1 ALPHA 1062
- 5.3.2 ANVS405
- 5.3.3 AST-004
- 5.3.4 MAP4343
- 5.3.5 Neuro-Cells
- 5.3.6 NVG-291
- 5.3.7 PRV-002
- 5.3.8 RHN002
- 5.3.9 ST266
- 5.4 Early-Stage Drugs – Preclinical
- 5.4.1 ACD856
- 5.4.2 ALP-495
- 5.4.3 ANG-3777
- 5.4.4 BCS-C01
- 5.4.5 Bryostatin
- 5.4.6 CEVA102
- 5.4.7 CM-EX-137
- 5.4.8 CMX-2043
- 5.4.9 COG1410
- 5.4.10 Exosome therapy
- 5.4.11 Fluorescently labeled peptide
- 5.4.12 Fv-Hsp72
- 5.4.13 IC 100
- 5.4.14 ILB
- 5.4.15 Itanapraced
- 5.4.16 JNS110
- 5.4.17 KLS-13019
- 5.4.18 LM22A-4
- 5.4.19 MD-021
- 5.4.20 MD-054
- 5.4.21 NA-184
- 5.4.22 N-acetyl-cysteine (NAC)
- 5.4.23 NoNO-SC
- 5.4.24 NTS-104
- 5.4.25 NTS-105
- 5.4.26 NXS-1002
- 5.4.27 NXS-1003
- 5.4.28 OSLO
- 5.4.29 P75NEURO
- 5.4.30 PNA 1,5
- 5.4.31 Psilocybin
- 5.4.32 QS100
- 5.4.33 RNS60
- 5.4.34 RYANODEX
- 5.4.35 SANA-013
- 5.4.36 SanFlow
- 5.4.37 Stem Cell Therapy
- 5.4.38 Stem Cell Therapy
- 5.4.39 SYN2
- 5.4.40 T-101
- 5.4.41 VENT-02
- 5.5 Early-Stage Drugs – Discovery
- 5.5.1 BPN14770 PDE4D Inhibitor
- 5.5.2 Drug for TBI
- 5.5.3 Drug for TBI
- 5.5.4 Drug for TBI
- 5.5.5 Drug for TBI
- 5.5.6 DYRK1A Inhibitor
- 5.5.7 HNPC-01
- 5.5.8 Large Molecules for TBI
- 5.5.9 NWL-283
- 5.5.10 PUR001
- 5.5.11 SYN-NCE
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 AivoCode LLP
- 9.2 AlphaCognition Inc
- 9.3 ALSP Inc
- 9.4 AlzeCure Pharma AB
- 9.5 Anagin Inc
- 9.6 Angion Biomedica Corp
- 9.7 Annovis Bio Inc
- 9.8 AntiRadical Therapeutics LLC
- 9.9 Astrocyte Pharmaceuticals Inc
- 9.10 Athersys Inc
- 9.11 Avanir Pharmaceuticals Inc
- 9.12 B Cell Solutions Inc
- 9.13 Beyond Barriers Therapeutics Inc
- 9.14 Biosplice Therapeutics Inc
- 9.15 CalciMedica Inc
- 9.16 Cellvation Inc
- 9.17 CereSpir Inc
- 9.18 Cognosci Inc
- 9.19 Eagle Pharmaceuticals Inc
- 9.20 Gryphon Therapeutics Inc
- 9.21 Hope Biosciences
- 9.22 Hopstem Biotechnology LLC
- 9.23 Ischemix Inc
- 9.24 Jupiter Neurosciences Inc
- 9.25 Levolta Pharmaceuticals Inc
- 9.26 Mapreg SAS
- 9.27 Mercaptor Discoveries Inc
- 9.28 NervGen Pharma Corp
- 9.29 NeuExcell Therapeutics Inc
- 9.30 NeurAegis Inc
- 9.31 NeurExo Sciences LLC
- 9.32 Neuronasal LLC
- 9.33 Neuropathix Inc
- 9.34 Neuroplast BV
- 9.35 NeuroTrauma Sciences LLC
- 9.36 New World Laboratories Inc
- 9.37 NoNO Inc
- 9.38 Noveome Biotherapeutics Inc
- 9.39 Nyrada Inc
- 9.40 Odyssey Group International, Inc
- 9.41 Oxeia Biopharmaceuticals Inc
- 9.42 Personalized Stem Cells Inc
- 9.43 PharmatrophiX Inc
- 9.44 POLYSAN Scientific & Technological Pharmaceutical Company
- 9.45 ProNeurogen Inc
- 9.46 Protheragen Inc
- 9.47 PurMinds NeuroPharma Inc
- 9.48 Qrons Inc
- 9.49 Resolys Bio Inc
- 9.50 Revalesio Corp
- 9.51 Revive Therapeutics Ltd
- 9.52 RHNanopharmacuticals LLC
- 9.53 Rubicon Biotechnology Inc
- 9.54 SanBio, Inc
- 9.55 Shinkei Therapeutics LLC
- 9.56 Synaptogenix Inc
- 9.57 Takeda
- 9.58 Tetra Therapeutics
- 9.59 Thera Neuropharma Inc
- 9.60 Theratome Bio Inc
- 9.61 TikoMed AB
- 9.62 Vasopharm GmbH
- 9.63 Ventus Therapeutics Inc
- 9.64 Vivazome Therapeutics Pty Ltd
- 9.65 Wesana Health
- 9.66 ZyVersa Therapeutics Inc
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 11. Appendix
- List of Tables
- Table 1.2 Number of Products under Development by Companies
- Table 1.3 Products under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - Cytoflavin/ POLYSAN Scientific & Technological Pharmaceutical Company
- Table 2.2 Clinical Trial Details - VAS203/Vasopharm GmbH
- Table 2.3 Clinical Trial Details - AVP-786/Avanir Pharmaceuticals Inc
- Table 2.4 Clinical Trial Details - CEVA101 /Cellvation Inc
- Table 2.5 Clinical Trial Details - Cinryze/Takeda
- Table 2.6 Clinical Trial Details - HB-adMSCs/Hope Biosciences
- Table 2.7 Clinical Trial Details - OXE103 /Oxeia Biopharmaceuticals Inc
- Table 2.8 Clinical Trial Details - SB623/SanBio, Inc
- Table 2.9 Clinical Trial Details - PRV-002/Odyssey Group International, Inc
- Table 3. 1 Regulatory Designations
- Table 4. 1 Inactive Drugs
- List of Figures
- Figure 1. 1 Number of Products under Development for Traumatic Brain Injury (TBI), 2023
- Figure 1. 2 Products by Top 5 Targets and Stage of Development for Traumatic Brain Injury (TBI), 2023
- Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Traumatic Brain Injury (TBI), 2023
- Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Traumatic Brain Injury (TBI), 2023
- Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Traumatic Brain Injury (TBI), 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.